nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Dactinomycin—testicular cancer	0.123	0.193	CbGbCtD
Tolvaptan—CYP3A4—Ifosfamide—testicular cancer	0.0867	0.137	CbGbCtD
Tolvaptan—ABCB1—Vinblastine—testicular cancer	0.0767	0.121	CbGbCtD
Tolvaptan—ABCB1—Cisplatin—testicular cancer	0.0704	0.111	CbGbCtD
Tolvaptan—ABCB1—Etoposide—testicular cancer	0.0691	0.109	CbGbCtD
Tolvaptan—ABCB1—Doxorubicin—testicular cancer	0.0472	0.0744	CbGbCtD
Tolvaptan—CYP3A4—Vinblastine—testicular cancer	0.046	0.0725	CbGbCtD
Tolvaptan—ABCB1—Methotrexate—testicular cancer	0.0457	0.0721	CbGbCtD
Tolvaptan—CYP3A4—Etoposide—testicular cancer	0.0414	0.0653	CbGbCtD
Tolvaptan—CYP3A4—Doxorubicin—testicular cancer	0.0283	0.0446	CbGbCtD
Tolvaptan—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00144	0.00394	CcSEcCtD
Tolvaptan—Malaise—Bleomycin—testicular cancer	0.00143	0.0039	CcSEcCtD
Tolvaptan—Angiopathy—Ifosfamide—testicular cancer	0.00141	0.00385	CcSEcCtD
Tolvaptan—Immune system disorder—Ifosfamide—testicular cancer	0.0014	0.00384	CcSEcCtD
Tolvaptan—Mediastinal disorder—Ifosfamide—testicular cancer	0.0014	0.00383	CcSEcCtD
Tolvaptan—Blood uric acid increased—Epirubicin—testicular cancer	0.0014	0.00381	CcSEcCtD
Tolvaptan—Feeling abnormal—Chlorambucil—testicular cancer	0.00138	0.00376	CcSEcCtD
Tolvaptan—Pulmonary embolism—Epirubicin—testicular cancer	0.00137	0.00374	CcSEcCtD
Tolvaptan—Ill-defined disorder—Dactinomycin—testicular cancer	0.00137	0.00374	CcSEcCtD
Tolvaptan—Hyperuricaemia—Doxorubicin—testicular cancer	0.00137	0.00373	CcSEcCtD
Tolvaptan—Malnutrition—Ifosfamide—testicular cancer	0.00135	0.0037	CcSEcCtD
Tolvaptan—Hyperkalaemia—Epirubicin—testicular cancer	0.00135	0.00368	CcSEcCtD
Tolvaptan—Renal failure—Etoposide—testicular cancer	0.00134	0.00367	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Doxorubicin—testicular cancer	0.00134	0.00366	CcSEcCtD
Tolvaptan—Discomfort—Bleomycin—testicular cancer	0.00133	0.00364	CcSEcCtD
Tolvaptan—Malaise—Dactinomycin—testicular cancer	0.00133	0.00364	CcSEcCtD
Tolvaptan—Decreased appetite—Vinblastine—testicular cancer	0.00133	0.00363	CcSEcCtD
Tolvaptan—Ecchymosis—Methotrexate—testicular cancer	0.00132	0.00362	CcSEcCtD
Tolvaptan—Urine output increased—Methotrexate—testicular cancer	0.00132	0.00362	CcSEcCtD
Tolvaptan—Urinary tract disorder—Cisplatin—testicular cancer	0.00132	0.00362	CcSEcCtD
Tolvaptan—Body temperature increased—Chlorambucil—testicular cancer	0.00132	0.00361	CcSEcCtD
Tolvaptan—Connective tissue disorder—Cisplatin—testicular cancer	0.00132	0.0036	CcSEcCtD
Tolvaptan—Urethral disorder—Cisplatin—testicular cancer	0.00131	0.00359	CcSEcCtD
Tolvaptan—Constipation—Vinblastine—testicular cancer	0.00131	0.00357	CcSEcCtD
Tolvaptan—Anaphylactic shock—Bleomycin—testicular cancer	0.00129	0.00353	CcSEcCtD
Tolvaptan—Blood uric acid increased—Doxorubicin—testicular cancer	0.00129	0.00353	CcSEcCtD
Tolvaptan—Pulmonary embolism—Doxorubicin—testicular cancer	0.00127	0.00346	CcSEcCtD
Tolvaptan—Feeling abnormal—Vinblastine—testicular cancer	0.00126	0.00344	CcSEcCtD
Tolvaptan—Ill-defined disorder—Ifosfamide—testicular cancer	0.00126	0.00343	CcSEcCtD
Tolvaptan—Hyperkalaemia—Doxorubicin—testicular cancer	0.00125	0.0034	CcSEcCtD
Tolvaptan—Cardiac disorder—Cisplatin—testicular cancer	0.00124	0.0034	CcSEcCtD
Tolvaptan—Discomfort—Dactinomycin—testicular cancer	0.00124	0.00339	CcSEcCtD
Tolvaptan—Ecchymosis—Epirubicin—testicular cancer	0.00124	0.00338	CcSEcCtD
Tolvaptan—Anorexia—Bleomycin—testicular cancer	0.00123	0.00336	CcSEcCtD
Tolvaptan—Hypersensitivity—Chlorambucil—testicular cancer	0.00123	0.00336	CcSEcCtD
Tolvaptan—Malaise—Ifosfamide—testicular cancer	0.00122	0.00333	CcSEcCtD
Tolvaptan—Urinary tract disorder—Etoposide—testicular cancer	0.00121	0.00331	CcSEcCtD
Tolvaptan—Polyuria—Methotrexate—testicular cancer	0.00121	0.00331	CcSEcCtD
Tolvaptan—Immune system disorder—Cisplatin—testicular cancer	0.00121	0.00331	CcSEcCtD
Tolvaptan—Mediastinal disorder—Cisplatin—testicular cancer	0.00121	0.0033	CcSEcCtD
Tolvaptan—Urethral disorder—Etoposide—testicular cancer	0.0012	0.00329	CcSEcCtD
Tolvaptan—Asthenia—Chlorambucil—testicular cancer	0.0012	0.00327	CcSEcCtD
Tolvaptan—Pruritus—Chlorambucil—testicular cancer	0.00118	0.00323	CcSEcCtD
Tolvaptan—Malnutrition—Cisplatin—testicular cancer	0.00117	0.00319	CcSEcCtD
Tolvaptan—Anorexia—Dactinomycin—testicular cancer	0.00115	0.00314	CcSEcCtD
Tolvaptan—Ecchymosis—Doxorubicin—testicular cancer	0.00115	0.00313	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00114	0.00313	CcSEcCtD
Tolvaptan—Diarrhoea—Chlorambucil—testicular cancer	0.00114	0.00312	CcSEcCtD
Tolvaptan—Cardiac disorder—Etoposide—testicular cancer	0.00114	0.00311	CcSEcCtD
Tolvaptan—Discomfort—Ifosfamide—testicular cancer	0.00114	0.00311	CcSEcCtD
Tolvaptan—Hypersensitivity—Vinblastine—testicular cancer	0.00113	0.00308	CcSEcCtD
Tolvaptan—Decreased appetite—Bleomycin—testicular cancer	0.00112	0.00307	CcSEcCtD
Tolvaptan—Angiopathy—Etoposide—testicular cancer	0.00111	0.00304	CcSEcCtD
Tolvaptan—Immune system disorder—Etoposide—testicular cancer	0.00111	0.00303	CcSEcCtD
Tolvaptan—Mediastinal disorder—Etoposide—testicular cancer	0.00111	0.00302	CcSEcCtD
Tolvaptan—Anaphylactic shock—Ifosfamide—testicular cancer	0.0011	0.00302	CcSEcCtD
Tolvaptan—Asthenia—Vinblastine—testicular cancer	0.0011	0.003	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Methotrexate—testicular cancer	0.00108	0.00296	CcSEcCtD
Tolvaptan—Nervous system disorder—Ifosfamide—testicular cancer	0.00108	0.00296	CcSEcCtD
Tolvaptan—Ill-defined disorder—Cisplatin—testicular cancer	0.00108	0.00296	CcSEcCtD
Tolvaptan—Skin disorder—Ifosfamide—testicular cancer	0.00107	0.00293	CcSEcCtD
Tolvaptan—Feeling abnormal—Bleomycin—testicular cancer	0.00106	0.00291	CcSEcCtD
Tolvaptan—Anorexia—Ifosfamide—testicular cancer	0.00105	0.00288	CcSEcCtD
Tolvaptan—Malaise—Cisplatin—testicular cancer	0.00105	0.00287	CcSEcCtD
Tolvaptan—Decreased appetite—Dactinomycin—testicular cancer	0.00105	0.00286	CcSEcCtD
Tolvaptan—Diarrhoea—Vinblastine—testicular cancer	0.00105	0.00286	CcSEcCtD
Tolvaptan—Dysgeusia—Etoposide—testicular cancer	0.00105	0.00286	CcSEcCtD
Tolvaptan—Renal impairment—Epirubicin—testicular cancer	0.00105	0.00286	CcSEcCtD
Tolvaptan—Body temperature increased—Bleomycin—testicular cancer	0.00102	0.00279	CcSEcCtD
Tolvaptan—Hypoglycaemia—Epirubicin—testicular cancer	0.00102	0.00278	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Epirubicin—testicular cancer	0.00102	0.00277	CcSEcCtD
Tolvaptan—Dizziness—Vinblastine—testicular cancer	0.00101	0.00276	CcSEcCtD
Tolvaptan—Hyponatraemia—Epirubicin—testicular cancer	0.000999	0.00273	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.000995	0.00272	CcSEcCtD
Tolvaptan—Feeling abnormal—Dactinomycin—testicular cancer	0.000993	0.00271	CcSEcCtD
Tolvaptan—Nausea—Chlorambucil—testicular cancer	0.000992	0.00271	CcSEcCtD
Tolvaptan—Ill-defined disorder—Etoposide—testicular cancer	0.000992	0.00271	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000986	0.00269	CcSEcCtD
Tolvaptan—Discomfort—Cisplatin—testicular cancer	0.000981	0.00268	CcSEcCtD
Tolvaptan—Renal impairment—Doxorubicin—testicular cancer	0.000967	0.00264	CcSEcCtD
Tolvaptan—Malaise—Etoposide—testicular cancer	0.000964	0.00263	CcSEcCtD
Tolvaptan—Breast disorder—Methotrexate—testicular cancer	0.000961	0.00262	CcSEcCtD
Tolvaptan—Decreased appetite—Ifosfamide—testicular cancer	0.00096	0.00262	CcSEcCtD
Tolvaptan—Headache—Vinblastine—testicular cancer	0.000958	0.00262	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000953	0.0026	CcSEcCtD
Tolvaptan—Body temperature increased—Dactinomycin—testicular cancer	0.000953	0.0026	CcSEcCtD
Tolvaptan—Anaphylactic shock—Cisplatin—testicular cancer	0.000952	0.0026	CcSEcCtD
Tolvaptan—Hypersensitivity—Bleomycin—testicular cancer	0.000952	0.0026	CcSEcCtD
Tolvaptan—Constipation—Ifosfamide—testicular cancer	0.000944	0.00258	CcSEcCtD
Tolvaptan—Hypoglycaemia—Doxorubicin—testicular cancer	0.000943	0.00258	CcSEcCtD
Tolvaptan—Loss of consciousness—Etoposide—testicular cancer	0.000939	0.00257	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000939	0.00257	CcSEcCtD
Tolvaptan—Nervous system disorder—Cisplatin—testicular cancer	0.000934	0.00255	CcSEcCtD
Tolvaptan—Blood creatinine increased—Epirubicin—testicular cancer	0.000932	0.00255	CcSEcCtD
Tolvaptan—Asthenia—Bleomycin—testicular cancer	0.000927	0.00253	CcSEcCtD
Tolvaptan—Dehydration—Epirubicin—testicular cancer	0.000925	0.00253	CcSEcCtD
Tolvaptan—Skin disorder—Cisplatin—testicular cancer	0.000925	0.00253	CcSEcCtD
Tolvaptan—Hyponatraemia—Doxorubicin—testicular cancer	0.000924	0.00252	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.00092	0.00251	CcSEcCtD
Tolvaptan—Pruritus—Bleomycin—testicular cancer	0.000914	0.0025	CcSEcCtD
Tolvaptan—Feeling abnormal—Ifosfamide—testicular cancer	0.00091	0.00249	CcSEcCtD
Tolvaptan—Nausea—Vinblastine—testicular cancer	0.000909	0.00248	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Epirubicin—testicular cancer	0.000909	0.00248	CcSEcCtD
Tolvaptan—Anorexia—Cisplatin—testicular cancer	0.000908	0.00248	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000904	0.00247	CcSEcCtD
Tolvaptan—Discomfort—Etoposide—testicular cancer	0.000899	0.00246	CcSEcCtD
Tolvaptan—Breast disorder—Epirubicin—testicular cancer	0.000899	0.00246	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000896	0.00245	CcSEcCtD
Tolvaptan—Hypersensitivity—Dactinomycin—testicular cancer	0.000888	0.00243	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000877	0.0024	CcSEcCtD
Tolvaptan—Body temperature increased—Ifosfamide—testicular cancer	0.000873	0.00238	CcSEcCtD
Tolvaptan—Anaphylactic shock—Etoposide—testicular cancer	0.000872	0.00238	CcSEcCtD
Tolvaptan—Asthenia—Dactinomycin—testicular cancer	0.000865	0.00236	CcSEcCtD
Tolvaptan—Blood creatinine increased—Doxorubicin—testicular cancer	0.000862	0.00236	CcSEcCtD
Tolvaptan—Dehydration—Doxorubicin—testicular cancer	0.000856	0.00234	CcSEcCtD
Tolvaptan—Skin disorder—Etoposide—testicular cancer	0.000847	0.00231	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000841	0.0023	CcSEcCtD
Tolvaptan—Breast disorder—Doxorubicin—testicular cancer	0.000832	0.00227	CcSEcCtD
Tolvaptan—Anorexia—Etoposide—testicular cancer	0.000831	0.00227	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000829	0.00226	CcSEcCtD
Tolvaptan—Decreased appetite—Cisplatin—testicular cancer	0.000828	0.00226	CcSEcCtD
Tolvaptan—Diarrhoea—Dactinomycin—testicular cancer	0.000825	0.00225	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000822	0.00225	CcSEcCtD
Tolvaptan—Hypersensitivity—Ifosfamide—testicular cancer	0.000814	0.00222	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000812	0.00222	CcSEcCtD
Tolvaptan—Renal failure—Methotrexate—testicular cancer	0.000805	0.0022	CcSEcCtD
Tolvaptan—Pollakiuria—Epirubicin—testicular cancer	0.000794	0.00217	CcSEcCtD
Tolvaptan—Asthenia—Ifosfamide—testicular cancer	0.000792	0.00216	CcSEcCtD
Tolvaptan—Feeling abnormal—Cisplatin—testicular cancer	0.000785	0.00214	CcSEcCtD
Tolvaptan—Pruritus—Ifosfamide—testicular cancer	0.000781	0.00213	CcSEcCtD
Tolvaptan—Hyperglycaemia—Epirubicin—testicular cancer	0.000776	0.00212	CcSEcCtD
Tolvaptan—Nausea—Bleomycin—testicular cancer	0.000768	0.0021	CcSEcCtD
Tolvaptan—Decreased appetite—Etoposide—testicular cancer	0.000758	0.00207	CcSEcCtD
Tolvaptan—Diarrhoea—Ifosfamide—testicular cancer	0.000756	0.00206	CcSEcCtD
Tolvaptan—Renal failure—Epirubicin—testicular cancer	0.000754	0.00206	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Etoposide—testicular cancer	0.000753	0.00206	CcSEcCtD
Tolvaptan—Body temperature increased—Cisplatin—testicular cancer	0.000753	0.00206	CcSEcCtD
Tolvaptan—Constipation—Etoposide—testicular cancer	0.000746	0.00204	CcSEcCtD
Tolvaptan—Pollakiuria—Doxorubicin—testicular cancer	0.000735	0.00201	CcSEcCtD
Tolvaptan—Dizziness—Ifosfamide—testicular cancer	0.00073	0.00199	CcSEcCtD
Tolvaptan—Urinary tract disorder—Methotrexate—testicular cancer	0.000726	0.00198	CcSEcCtD
Tolvaptan—Urethral disorder—Methotrexate—testicular cancer	0.000721	0.00197	CcSEcCtD
Tolvaptan—Feeling abnormal—Etoposide—testicular cancer	0.000719	0.00196	CcSEcCtD
Tolvaptan—Hyperglycaemia—Doxorubicin—testicular cancer	0.000718	0.00196	CcSEcCtD
Tolvaptan—Nausea—Dactinomycin—testicular cancer	0.000716	0.00196	CcSEcCtD
Tolvaptan—Hypersensitivity—Cisplatin—testicular cancer	0.000701	0.00192	CcSEcCtD
Tolvaptan—Renal failure—Doxorubicin—testicular cancer	0.000697	0.0019	CcSEcCtD
Tolvaptan—Body temperature increased—Etoposide—testicular cancer	0.000689	0.00188	CcSEcCtD
Tolvaptan—Asthenia—Cisplatin—testicular cancer	0.000683	0.00187	CcSEcCtD
Tolvaptan—Cardiac disorder—Methotrexate—testicular cancer	0.000682	0.00186	CcSEcCtD
Tolvaptan—Urinary tract disorder—Epirubicin—testicular cancer	0.00068	0.00186	CcSEcCtD
Tolvaptan—Connective tissue disorder—Epirubicin—testicular cancer	0.000676	0.00185	CcSEcCtD
Tolvaptan—Urethral disorder—Epirubicin—testicular cancer	0.000675	0.00184	CcSEcCtD
Tolvaptan—Angiopathy—Methotrexate—testicular cancer	0.000667	0.00182	CcSEcCtD
Tolvaptan—Immune system disorder—Methotrexate—testicular cancer	0.000664	0.00181	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methotrexate—testicular cancer	0.000663	0.00181	CcSEcCtD
Tolvaptan—Nausea—Ifosfamide—testicular cancer	0.000656	0.00179	CcSEcCtD
Tolvaptan—Diarrhoea—Cisplatin—testicular cancer	0.000651	0.00178	CcSEcCtD
Tolvaptan—Hypersensitivity—Etoposide—testicular cancer	0.000643	0.00176	CcSEcCtD
Tolvaptan—Malnutrition—Methotrexate—testicular cancer	0.00064	0.00175	CcSEcCtD
Tolvaptan—Cardiac disorder—Epirubicin—testicular cancer	0.000639	0.00174	CcSEcCtD
Tolvaptan—Urinary tract disorder—Doxorubicin—testicular cancer	0.000629	0.00172	CcSEcCtD
Tolvaptan—Dysgeusia—Methotrexate—testicular cancer	0.000627	0.00171	CcSEcCtD
Tolvaptan—Asthenia—Etoposide—testicular cancer	0.000626	0.00171	CcSEcCtD
Tolvaptan—Connective tissue disorder—Doxorubicin—testicular cancer	0.000626	0.00171	CcSEcCtD
Tolvaptan—Angiopathy—Epirubicin—testicular cancer	0.000624	0.00171	CcSEcCtD
Tolvaptan—Urethral disorder—Doxorubicin—testicular cancer	0.000624	0.00171	CcSEcCtD
Tolvaptan—Immune system disorder—Epirubicin—testicular cancer	0.000622	0.0017	CcSEcCtD
Tolvaptan—Mediastinal disorder—Epirubicin—testicular cancer	0.00062	0.00169	CcSEcCtD
Tolvaptan—Pruritus—Etoposide—testicular cancer	0.000617	0.00169	CcSEcCtD
Tolvaptan—Malnutrition—Epirubicin—testicular cancer	0.000599	0.00164	CcSEcCtD
Tolvaptan—Diarrhoea—Etoposide—testicular cancer	0.000597	0.00163	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methotrexate—testicular cancer	0.000594	0.00162	CcSEcCtD
Tolvaptan—Cardiac disorder—Doxorubicin—testicular cancer	0.000591	0.00161	CcSEcCtD
Tolvaptan—Dysgeusia—Epirubicin—testicular cancer	0.000587	0.0016	CcSEcCtD
Tolvaptan—Angiopathy—Doxorubicin—testicular cancer	0.000578	0.00158	CcSEcCtD
Tolvaptan—Malaise—Methotrexate—testicular cancer	0.000577	0.00158	CcSEcCtD
Tolvaptan—Dizziness—Etoposide—testicular cancer	0.000577	0.00158	CcSEcCtD
Tolvaptan—Immune system disorder—Doxorubicin—testicular cancer	0.000575	0.00157	CcSEcCtD
Tolvaptan—Mediastinal disorder—Doxorubicin—testicular cancer	0.000574	0.00157	CcSEcCtD
Tolvaptan—Nausea—Cisplatin—testicular cancer	0.000566	0.00154	CcSEcCtD
Tolvaptan—Ill-defined disorder—Epirubicin—testicular cancer	0.000556	0.00152	CcSEcCtD
Tolvaptan—Malnutrition—Doxorubicin—testicular cancer	0.000554	0.00151	CcSEcCtD
Tolvaptan—Headache—Etoposide—testicular cancer	0.000546	0.00149	CcSEcCtD
Tolvaptan—Dysgeusia—Doxorubicin—testicular cancer	0.000543	0.00148	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000541	0.00148	CcSEcCtD
Tolvaptan—Malaise—Epirubicin—testicular cancer	0.00054	0.00148	CcSEcCtD
Tolvaptan—Discomfort—Methotrexate—testicular cancer	0.000538	0.00147	CcSEcCtD
Tolvaptan—Syncope—Epirubicin—testicular cancer	0.000537	0.00147	CcSEcCtD
Tolvaptan—Loss of consciousness—Epirubicin—testicular cancer	0.000527	0.00144	CcSEcCtD
Tolvaptan—Anaphylactic shock—Methotrexate—testicular cancer	0.000522	0.00143	CcSEcCtD
Tolvaptan—Nausea—Etoposide—testicular cancer	0.000518	0.00142	CcSEcCtD
Tolvaptan—Ill-defined disorder—Doxorubicin—testicular cancer	0.000514	0.0014	CcSEcCtD
Tolvaptan—Nervous system disorder—Methotrexate—testicular cancer	0.000512	0.0014	CcSEcCtD
Tolvaptan—Skin disorder—Methotrexate—testicular cancer	0.000507	0.00139	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000506	0.00138	CcSEcCtD
Tolvaptan—Discomfort—Epirubicin—testicular cancer	0.000504	0.00138	CcSEcCtD
Tolvaptan—Malaise—Doxorubicin—testicular cancer	0.0005	0.00137	CcSEcCtD
Tolvaptan—Dry mouth—Epirubicin—testicular cancer	0.000499	0.00136	CcSEcCtD
Tolvaptan—Anorexia—Methotrexate—testicular cancer	0.000498	0.00136	CcSEcCtD
Tolvaptan—Syncope—Doxorubicin—testicular cancer	0.000497	0.00136	CcSEcCtD
Tolvaptan—Anaphylactic shock—Epirubicin—testicular cancer	0.000489	0.00134	CcSEcCtD
Tolvaptan—Loss of consciousness—Doxorubicin—testicular cancer	0.000487	0.00133	CcSEcCtD
Tolvaptan—Shock—Epirubicin—testicular cancer	0.000481	0.00131	CcSEcCtD
Tolvaptan—Nervous system disorder—Epirubicin—testicular cancer	0.000479	0.00131	CcSEcCtD
Tolvaptan—Skin disorder—Epirubicin—testicular cancer	0.000475	0.0013	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000469	0.00128	CcSEcCtD
Tolvaptan—Discomfort—Doxorubicin—testicular cancer	0.000466	0.00127	CcSEcCtD
Tolvaptan—Anorexia—Epirubicin—testicular cancer	0.000466	0.00127	CcSEcCtD
Tolvaptan—Dry mouth—Doxorubicin—testicular cancer	0.000462	0.00126	CcSEcCtD
Tolvaptan—Decreased appetite—Methotrexate—testicular cancer	0.000454	0.00124	CcSEcCtD
Tolvaptan—Anaphylactic shock—Doxorubicin—testicular cancer	0.000452	0.00124	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000451	0.00123	CcSEcCtD
Tolvaptan—Shock—Doxorubicin—testicular cancer	0.000445	0.00122	CcSEcCtD
Tolvaptan—Nervous system disorder—Doxorubicin—testicular cancer	0.000444	0.00121	CcSEcCtD
Tolvaptan—Skin disorder—Doxorubicin—testicular cancer	0.000439	0.0012	CcSEcCtD
Tolvaptan—Anorexia—Doxorubicin—testicular cancer	0.000431	0.00118	CcSEcCtD
Tolvaptan—Feeling abnormal—Methotrexate—testicular cancer	0.000431	0.00118	CcSEcCtD
Tolvaptan—Decreased appetite—Epirubicin—testicular cancer	0.000425	0.00116	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000422	0.00115	CcSEcCtD
Tolvaptan—Constipation—Epirubicin—testicular cancer	0.000418	0.00114	CcSEcCtD
Tolvaptan—Body temperature increased—Methotrexate—testicular cancer	0.000413	0.00113	CcSEcCtD
Tolvaptan—Feeling abnormal—Epirubicin—testicular cancer	0.000403	0.0011	CcSEcCtD
Tolvaptan—Decreased appetite—Doxorubicin—testicular cancer	0.000393	0.00107	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000391	0.00107	CcSEcCtD
Tolvaptan—Constipation—Doxorubicin—testicular cancer	0.000387	0.00106	CcSEcCtD
Tolvaptan—Body temperature increased—Epirubicin—testicular cancer	0.000386	0.00106	CcSEcCtD
Tolvaptan—Hypersensitivity—Methotrexate—testicular cancer	0.000385	0.00105	CcSEcCtD
Tolvaptan—Asthenia—Methotrexate—testicular cancer	0.000375	0.00102	CcSEcCtD
Tolvaptan—Feeling abnormal—Doxorubicin—testicular cancer	0.000373	0.00102	CcSEcCtD
Tolvaptan—Pruritus—Methotrexate—testicular cancer	0.00037	0.00101	CcSEcCtD
Tolvaptan—Hypersensitivity—Epirubicin—testicular cancer	0.00036	0.000984	CcSEcCtD
Tolvaptan—Body temperature increased—Doxorubicin—testicular cancer	0.000358	0.000977	CcSEcCtD
Tolvaptan—Diarrhoea—Methotrexate—testicular cancer	0.000357	0.000976	CcSEcCtD
Tolvaptan—Asthenia—Epirubicin—testicular cancer	0.000351	0.000958	CcSEcCtD
Tolvaptan—Pruritus—Epirubicin—testicular cancer	0.000346	0.000945	CcSEcCtD
Tolvaptan—Dizziness—Methotrexate—testicular cancer	0.000345	0.000944	CcSEcCtD
Tolvaptan—Diarrhoea—Epirubicin—testicular cancer	0.000335	0.000914	CcSEcCtD
Tolvaptan—Hypersensitivity—Doxorubicin—testicular cancer	0.000333	0.00091	CcSEcCtD
Tolvaptan—Headache—Methotrexate—testicular cancer	0.000327	0.000894	CcSEcCtD
Tolvaptan—Asthenia—Doxorubicin—testicular cancer	0.000325	0.000887	CcSEcCtD
Tolvaptan—Dizziness—Epirubicin—testicular cancer	0.000323	0.000883	CcSEcCtD
Tolvaptan—Pruritus—Doxorubicin—testicular cancer	0.00032	0.000874	CcSEcCtD
Tolvaptan—Nausea—Methotrexate—testicular cancer	0.00031	0.000848	CcSEcCtD
Tolvaptan—Diarrhoea—Doxorubicin—testicular cancer	0.00031	0.000846	CcSEcCtD
Tolvaptan—Headache—Epirubicin—testicular cancer	0.000306	0.000837	CcSEcCtD
Tolvaptan—Dizziness—Doxorubicin—testicular cancer	0.000299	0.000817	CcSEcCtD
Tolvaptan—Nausea—Epirubicin—testicular cancer	0.00029	0.000793	CcSEcCtD
Tolvaptan—Headache—Doxorubicin—testicular cancer	0.000283	0.000774	CcSEcCtD
Tolvaptan—Nausea—Doxorubicin—testicular cancer	0.000269	0.000734	CcSEcCtD
